XT
ACRS icon

XTX Topco’s Aclaris Therapeutics ACRS Stock Holding History

XTX Topco’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$367K Sell
97,774
-15,138
-13% -$51.1K 0.01% 2303
2025
Q4 		$340K Buy
112,912
+48,987
+77% +$124K 0.01% 1957
2025
Q3 		$121K Buy
63,925
+40,008
+167% +$69.8K 0.01% 1983
2025
Q2 		$34K Buy
+23,917
New +$32.4K ﹤0.01% 2085
2025
Q1 		– Sell
-44,685
Closed -$111K – 2340
2024
Q4 		$111K Buy
+44,685
New +$111K 0.01% 1747
2024
Q3 		– Sell
-24,452
Closed -$26.9K – 2026
2024
Q2 		$26.9K Sell
24,452
-98,648
-80% -$116K ﹤0.01% 1583
2024
Q1 		$153K Sell
123,100
-255,200
-67% -$304K 0.02% 1257
2023
Q4 		$397K Buy
+378,300
New +$1.15M 0.09% 405
2023
Q1 		– Sell
-12,423
Closed -$196K – 1228
2022
Q4 		$196K Buy
+12,423
New +$200K 0.04% 851

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

XTX Topco's ACRS Position: Q1 2026 in Review

XTX Topco reduced its Aclaris Therapeutics (ACRS) stake by 13% in Q1 2026, selling an estimated $51.1K and leaving 97,774 shares worth $367K. The position accounts for 0.01% of the portfolio, ranked #2303.

XTX Topco first reported a position in ACRS in Q4 2022 and has held it in 9 quarters since. The position peaked at $397K in Q4 2023. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • XTX Topco held 97,774 shares of Aclaris Therapeutics worth $367K as of Q1 2026.
  • XTX Topco sold 15,138 Aclaris Therapeutics shares in Q1 2026, an estimated $51.1K.
  • Aclaris Therapeutics made up 0.01% of XTX Topco's portfolio in Q1 2026, its #2303 holding.
  • XTX Topco first reported a position in Aclaris Therapeutics in Q4 2022 and has held it in 9 quarters since.
  • XTX Topco's Aclaris Therapeutics position peaked at $397K in Q4 2023.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.